SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending following FDA clearance to use its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 trial, a crucial manufacturing milestone for its breast cancer immunotherapy. The community is actively discussing this as a significant de-risking event for the company's Biologics License Application, fueling speculation around a potential short squeeze due to high borrow rates and a notably tight float. Investor sentiment is further buoyed by observed consistent insider buying, reinforcing confidence in the stock's future trajectory.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to intense community discussion centered on its ultra-low share float and significant short interest, leading to strong speculation about a potential short squeeze. Traders are keenly drawing comparisons to past high-volatility runners within the "Hong Kong low float" theme, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement. The company's recent fiscal year financial results reporting revenue growth in security-related engineering services also contribute to the bullish sentiment among market participants.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is a major talking point following news of a Neutron rocket tank rupture during qualification testing. The community is split, with many highlighting it as a standard and intentional stress test crucial for validating structural limits, akin to industry peers, while others are concerned about potential development delays. This critical step for the future Neutron rocket is unfolding amidst Rocket Lab's strong Electron launch cadence and growing defense sector presence.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics is currently trending as investors debate its valuation following updates on its JANX008 study and subsequent analyst re-ratings, which occurred after prior mixed data from its JANX007 program caused a significant price decline. The community is heavily focused on the stock trading below its cash value, fueling discussions around a potential short squeeze and persistent rumors of a Merck buyout. Despite some frustration with market action and management, many believe the stock is oversold and poised for a rebound, reflecting the volatile nature of clinical-stage biotech.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is experiencing significant bullish momentum after the U.S. government, via NOAA, streamlined deep-sea mining permits, signaling a faster path to commercial recovery for critical minerals. This regulatory de-risking, coupled with an upcoming Congressional hearing featuring TMC's CEO, is driving community discussions around national security priorities, long-term value, and the potential for a substantial short squeeze.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors anticipate its upcoming Q4 earnings report, with community sentiment sharply divided between hopes for AR/AI advancements and concerns over historical post-earnings declines. The company also faces increasing scrutiny regarding potential global social media bans for minors, which is adding significant regulatory pressure to its user growth outlook, while ongoing discussions about CEO share sales continue to fuel investor debate.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is trending following its earnings report, which delivered revenue declines and cautious 2026 guidance, alongside a strategic acquisition of Mentee Robotics to expand into humanoid AI. Community sentiment is deeply divided, with many expressing frustration over the stock's continued decline despite this expansion and an earlier major US automaker deal. Investors are grappling with whether the stock is significantly undervalued or experiencing sustained selling pressure, amidst concerns about valuation and market perception.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing strong upward momentum as reports circulate about plans to spin off and list its AI chip unit, Pingtouge/T-Head Semiconductor. This potential strategic move is igniting widespread investor enthusiasm, with the community actively discussing a significant breakout for the stock. The development reinforces Alibaba's robust standing in China's burgeoning AI and cloud sectors, contributing to a broader positive sentiment for Chinese tech.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending due to a significant new investment from Steve Cohen's Point72, signaling strong institutional confidence in the company. This comes as the community eagerly awaits initial sales data for their recently launched fibromyalgia drug, Tonmya, and anticipates updates on its promising Lyme disease prevention pipeline. Despite some historical skepticism, many believe this institutional backing, combined with future commercial execution, positions the biotech for a notable re-evaluation.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed (PAVM) is experiencing significant market attention following its subsidiary Lucid Diagnostics securing a pivotal U.S. Department of Veterans Affairs contract for its EsoGuard esophageal DNA test. This agreement, poised to expand precancer screening for millions of veterans, has ignited bullish discussions around a potential short squeeze given the stock's low float, though some community members are highlighting historical volatility and concerns about potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Why Did Aethlon Medical Stock Tumble Over 12% Today?

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 

Equity

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 


Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million Aethlon Medical Announces Pricing of a Private...

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier Binds to Extracellular Vesicles in Long COVID patient samples and Decreases...

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update PR Newswire SAN DIEGO, Nov. 12, 2025...

What to Expect from Aethlon Medical's Earnings

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference...

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.

Aethlon Medical Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

AEMD
Aethlon Medical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AEMD News

AEMDAethlon Medical Inc